Gold seed markers for improved set-up accuracy during high dose radiotherapy for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN76286772

Enrollment

Registered

2004-09-30

Start date

2003-05-21

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Prostate Cancer Prostate

Interventions

1. Clinical trial 2. Randomised trial 2.1 Full bladder, empty rectum 2.2 Full bladder, full rectum 2.3 Empty bladder, empty rectum 2.4 Empty bladder, full rectum

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with prostate cancer undergoing radiotherapy. Added 29 July 2008: 1. Histologically confirmed, previously untreated, locally confined adenocarcinoma of the prostate (T1-T3a, NO, MO) 2. PSA <50NG/ML prior t any hormone therapy 3. No other malignancy within the previous 5 years 4. No indwelling urinary catheter 5. The use of neoadjuvant hormone therapy is permitted, but not mandatory

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Prior to July 2008: 1. Prostate position and movement 2. Radiation dose to tumour and normal tissues 3. Toxicity 4. Quality of life 5. Biochemical relapse free survival 6. Overall survival Modified on 23 July 2008 - primary end points as follows: 1. Determination of magnitude of set-up errors in radiotherapy of prostate cancer using current and alternative set-up procedures 2. Early and late treatment toxicity 3. Biochemical (PSA) relapse free survival 4. Overall survival will also be recorded, but the study is not large enough to detect any difference between the groups	—

Measure

Time frame

Prior to July 2008: 1. Prostate position and movement 2. Radiation dose to tumour and normal tissues 3. Toxicity 4. Quality of life 5. Biochemical relapse free survival 6. Overall survival Modified on 23 July 2008 - primary end points as follows: 1. Determination of magnitude of set-up errors in radiotherapy of prostate cancer using current and alternative set-up procedures 2. Early and late treatment toxicity 3. Biochemical (PSA) relapse free survival 4. Overall survival will also be recorded, but the study is not large enough to detect any difference between the groups

—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026